- Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis The New York Times
- Wall Street Breakfast Podcast: Kenvue In Focus Seeking Alpha
- Evercore ISI cuts Kenvue stock price target to $18 on FDA acetaminophen review Investing.com
- Tylenol maker rebounds a day after Trump’s unfounded claims about its safety Waco Tribune-Herald
- Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? – Stocktwits Beritasriwijaya.co.id
Source link
